UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Spontaneous abrogation of the G2 DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients

The Journal of clinical investigation, 2011-01, Vol.121 (1), p.184-194

2011

Volltextzugriff (PDF)

Novel fusion between the breakpoint cluster region and platelet‐derived growth factor receptor‐alpha genes in a patient with chronic myeloid leukemia‐like neoplasm: undetectable residual disease after imatinib therapy

European journal of haematology, 2015-11, Vol.95 (5), p.480-483

2015

Volltextzugriff (PDF)

Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment

Leukemia & lymphoma, 2014-08, Vol.55 (8), p.1854-1860

2014

Volltextzugriff (PDF)

Normal levels of peripheral CD19+CD5+ CLL‐like cells: Toward a defined threshold for CLL follow‐up—A GEIL‐GOELAMS study

Cytometry. Part B, Clinical cytometry, 2011-11, Vol.80B (6), p.346-353

2011

Volltextzugriff (PDF)

Non-MALT marginal zone lymphoma

Current opinion in hematology, 2011-07, Vol.18 (4), p.273-279

2011

Volltextzugriff (PDF)

Splenic marginal zone lymphoma: current knowledge and future directions

Oncology (Williston Park, N.Y.), 2012-02, Vol.26 (2), p.194-202

2012

Volltextzugriff (PDF)

BCL-2 and Mutant NRAS Interact Physically and Functionally in a Mouse Model of Progressive Myelodysplasia

Cancer research (Chicago, Ill.), 2007-12, Vol.67 (24), p.11657-11667

2007

Volltextzugriff (PDF)

DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies

Oncotarget, 2015-10, Vol.6 (32), p.32494-32508

2015

Volltextzugriff (PDF)

GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways

Journal of hematology and oncology, 2016-01, Vol.9 (5), p.5-5, Article 5

2016

Volltextzugriff (PDF)

Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes

Leukemia research, 2013-03, Vol.37 (3), p.312-319

2013

Volltextzugriff (PDF)

Lymphomatous lesions

Annales de pathologie, 2008-11, Vol.28 Spec No 1 (1), p.S80-S81

2008

Volltextzugriff (PDF)

Les lésions lymphomateuses

Annales de pathologie, 2008-11, Vol.28 (1), p.S80-S81

2008

Volltextzugriff (PDF)

Phagocytic myeloma cells: report of a case and review of the literature

Hématologie, 2017-01, Vol.23 (1), p.57-60

2017

Volltextzugriff (PDF)

Successful rituximab treatment of an EBV-related lymphoproliferative disease arising after autologous transplantation for angioimmunoblastic T-cell lymphoma

The hematology journal : the official journal of the European Haematology Association, 2002, Vol.3 (6), p.317-320

2002

Volltextzugriff (PDF)

Biological Description of 109 Cases of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) from the French Network of BPDCN

Blood, 2015-12, Vol.126 (23), p.3812-3812

2015

Volltextzugriff (PDF)

Mutant BCL2 Co-Operates with CBFβ/PEBP2β-MYH11 to Promote Expansion of Leukemia Initiating Cells with a Predominantly Pro-Apoptotic Mechanism Via Recruitment of Ras-GTP In a Mouse Model of Progressive Acute Myeloid Leukemia

Blood, 2010-11, Vol.116 (21), p.1050-1050

2010

Volltextzugriff (PDF)

NRAS:BCL-2 Complex Localization Determines Anti-Apoptotic Features Associated with Progressive Disease in Myelodysplastic Syndromes (MDS)

Blood, 2012-11, Vol.120 (21), p.3835-3835

2012

Volltextzugriff (PDF)

Aplastic anemia and paroxysmal nocturnal hemoglobinuria: a follow-up study of the glycosylphosphatidylinositol-anchored proteins defect

The hematology journal : the official journal of the European Haematology Association, 2000, Vol.1 (4), p.250-253

2000

Volltextzugriff (PDF)

Spontaneous abrogation of the G^sub 2^ DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients

The Journal of clinical investigation, 2011-01, Vol.121 (1), p.184

2011

Volltextzugriff (PDF)

Spontaneous abrogation of the [G.sub.2] DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients

The Journal of clinical investigation, 2011-01, Vol.121 (1), p.184

2011

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(40)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(22)
Science & Technology
(22)
Humans
(19)
Female
(10)
Middle Aged
(10)
Adult
(9)
Hematology
(8)
Male
(8)
Oncology
(8)
Aged
(6)
Flow Cytometry
(6)
Animals
(5)
Biological And Medical Sciences
(5)
Child
(5)
Hematologic And Hematopoietic Diseases
(5)
Medical Sciences
(5)
Mice, Transgenic
(5)
Mutation
(5)
Myelodysplastic Syndromes - Genetics
(5)
Acute Disease
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic Syndrome

Spontaneous abrogation of the G2 DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients

Novel fusion between the breakpoint cluster region and platelet‐derived growth factor receptor‐alpha genes in a patient with chronic myeloid leukemia‐like neoplasm: undetectable residual disease after imatinib therapy

Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment

BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells

Normal levels of peripheral CD19+CD5+ CLL‐like cells: Toward a defined threshold for CLL follow‐up—A GEIL‐GOELAMS study

Non-MALT marginal zone lymphoma

Splenic marginal zone lymphoma: current knowledge and future directions

BCL-2 and Mutant NRAS Interact Physically and Functionally in a Mouse Model of Progressive Myelodysplasia

DNA-mediated adjuvant immunotherapy extends survival in two different mouse models of myeloid malignancies

GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways

Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes

Lymphomatous lesions

Les lésions lymphomateuses

Phagocytic myeloma cells: report of a case and review of the literature

Successful rituximab treatment of an EBV-related lymphoproliferative disease arising after autologous transplantation for angioimmunoblastic T-cell lymphoma

Efficacy of ABT-737, a BCL-2 Inhibitor, in an NRAS/BCL2 Mouse Model of High Risk Myelodysplasia (HR-MDS) By Targeting Pathways Identified By Gene Expression Profiling

Biological Description of 109 Cases of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) from the French Network of BPDCN

BCL-2 Inhibition with ABT-737 Prolongs Survival in an NRAS/BCL2-Mediated MOUSE MODEL of Myelodyspastic Syndrome (MDS) Progressing to ACUTE Myelogenous Leukemia (AML) by Targeting Leukemia Initiating CELLS

Mutant BCL2 Co-Operates with CBFβ/PEBP2β-MYH11 to Promote Expansion of Leukemia Initiating Cells with a Predominantly Pro-Apoptotic Mechanism Via Recruitment of Ras-GTP In a Mouse Model of Progressive Acute Myeloid Leukemia

NRAS:BCL-2 Complex Localization Determines Anti-Apoptotic Features Associated with Progressive Disease in Myelodysplastic Syndromes (MDS)

Aplastic anemia and paroxysmal nocturnal hemoglobinuria: a follow-up study of the glycosylphosphatidylinositol-anchored proteins defect

Spontaneous abrogation of the G^sub 2^ DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients

Spontaneous abrogation of the [G.sub.2] DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients

ABT-737 Targets Leukemic Stem Cells In Mouse Models of Mutant NRASD12/hBCL-2- Mediated Acute Myeloid Leukemia Progression with Increased Survival

Suchergebnisse filtern